Audited Financial Results (Standalone and Consolidated) for quarter and year ended 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.2 pts more than Nifty Microcap 250 and 9.3 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eiko Lifesciences reported strong financial performance for FY26 ending March 2026. Standalone revenue grew 9% to Rs 3,249 lakhs while consolidated revenue jumped 40% to Rs 5,271 lakhs, driven by new logistics subsidiary and higher specialty chemicals demand. Net profit surged over 100% on standalone (Rs 358 lakhs vs Rs 174 lakhs) and 130% on consolidated (Rs 532 lakhs vs Rs 232 lakhs). EPS doubled to Rs 3.26 consolidated. The company raised Rs 749 lakhs via equity shares and warrants in January 2026, and acquired 31.68% stake in SSM Formulations Private Limited as an associate. The auditor issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong profit growth and clean audit opinion are positive for shareholders. The 40% revenue growth and more than doubling of PAT demonstrates operational leverage and successful diversification into logistics. The fundraise and acquisitions position the company for continued expansion.